PL340109A1 - Method of obtaining analogues of nucleosides - Google Patents

Method of obtaining analogues of nucleosides

Info

Publication number
PL340109A1
PL340109A1 PL00340109A PL34010900A PL340109A1 PL 340109 A1 PL340109 A1 PL 340109A1 PL 00340109 A PL00340109 A PL 00340109A PL 34010900 A PL34010900 A PL 34010900A PL 340109 A1 PL340109 A1 PL 340109A1
Authority
PL
Poland
Prior art keywords
nucleosides
obtaining analogues
analogues
obtaining
Prior art date
Application number
PL00340109A
Other languages
English (en)
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PL340109A1 publication Critical patent/PL340109A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14Pyrrolo-pyrimidine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
PL00340109A 1999-05-11 2000-05-11 Method of obtaining analogues of nucleosides PL340109A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13365199P 1999-05-11 1999-05-11

Publications (1)

Publication Number Publication Date
PL340109A1 true PL340109A1 (en) 2000-11-20

Family

ID=22459680

Family Applications (1)

Application Number Title Priority Date Filing Date
PL00340109A PL340109A1 (en) 1999-05-11 2000-05-11 Method of obtaining analogues of nucleosides

Country Status (22)

Country Link
US (1) US6271370B1 (forum.php)
EP (1) EP1052264B1 (forum.php)
JP (1) JP2001011092A (forum.php)
KR (1) KR100403900B1 (forum.php)
CN (1) CN1275575A (forum.php)
AR (1) AR028991A1 (forum.php)
AT (1) ATE291582T1 (forum.php)
AU (1) AU3401100A (forum.php)
BR (1) BR0002089A (forum.php)
CA (1) CA2307951A1 (forum.php)
CZ (1) CZ20001710A3 (forum.php)
DE (1) DE60018833D1 (forum.php)
HU (1) HUP0001843A3 (forum.php)
ID (1) ID25992A (forum.php)
IL (1) IL136027A0 (forum.php)
IN (1) IN186850B (forum.php)
MX (1) MXPA00004532A (forum.php)
PL (1) PL340109A1 (forum.php)
RU (1) RU2200738C2 (forum.php)
TR (1) TR200001340A2 (forum.php)
YU (1) YU25500A (forum.php)
ZA (1) ZA200002263B (forum.php)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200519106A (en) 2003-05-02 2005-06-16 Novartis Ag Organic compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP1773856B1 (en) * 2004-07-21 2012-02-01 Pharmasset, Inc. Preparation of alkyl-substituted 2-deoxy-2-fluoro-d-ribofuranosyl pyrimidines and purines and their derivatives
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
JP5138585B2 (ja) * 2005-05-05 2013-02-06 アーディア・バイオサイエンシーズ・インコーポレイテッド Hivの処置のための非ヌクレオシド逆転写酵素インヒビターとしてのジアリル−プリン、−アザプリンおよび−デアザプリン
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
WO2007017670A1 (en) 2005-08-08 2007-02-15 Argenta Discovery Ltd. Bicyclo[2.2.]hept-7-ylamine derivatives and their uses
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
EP2532677A1 (en) 2005-10-21 2012-12-12 Novartis AG Human antibodies against il13 and therapeutic uses
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
JP2010504933A (ja) 2006-09-29 2010-02-18 ノバルティス アーゲー Pi3k脂質キナーゼ阻害剤としてのピラゾロピリミジン
BRPI0718266A2 (pt) 2006-10-30 2014-01-07 Novartis Ag Compostos heterocíclicos como agentes anti-inflamatórios.
DK2229358T3 (da) 2007-12-14 2011-07-04 Pulmagen Therapeutics Asthma Ltd Indoler og deres terapeutiske anvendelse
WO2009079412A2 (en) * 2007-12-14 2009-06-25 Ardea Biosciences Inc. Reverse transcriptase inhibitors
WO2009087224A1 (en) 2008-01-11 2009-07-16 Novartis Ag Pyrimidines as kinase inhibitors
TW201031406A (en) 2009-01-29 2010-09-01 Novartis Ag Substituted benzimidazoles for the treatment of astrocytomas
WO2010094956A1 (en) 2009-02-17 2010-08-26 Pulmagen Therapeutics (Inflammation) Limited. Triazolopyridine derivatives as p38 map kinase inhibitors
GB0902648D0 (en) 2009-02-17 2009-04-01 Argenta Discovery Ltd Pharmaceutical compounds and compositions
US8927513B2 (en) * 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
WO2011018454A1 (en) 2009-08-12 2011-02-17 Novartis Ag Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
MX2012002066A (es) 2009-08-17 2012-03-29 Intellikine Inc Compuestos heterociclicos y usos de los mismos.
BR112012008061A2 (pt) 2009-08-20 2016-03-01 Novartis Ag compostos de oxima heterocíclica
GB201009731D0 (en) 2010-06-10 2010-07-21 Pulmagen Therapeutics Inflamma Kinase inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
EP2673277A1 (en) 2011-02-10 2013-12-18 Novartis AG [1, 2, 4]triazolo [4, 3 -b]pyridazine compounds as inhibitors of the c-met tyrosine kinase
EP2678016B1 (en) 2011-02-23 2016-08-10 Intellikine, LLC Heterocyclic compounds and uses thereof
MX2013009767A (es) 2011-02-25 2013-10-01 Irm Llc Compuestos y composiciones como inhibidores de trk.
EA026655B1 (ru) 2011-09-15 2017-05-31 Новартис Аг 6-ЗАМЕЩЕННЫЕ 3-(ХИНОЛИН-6-ИЛТИО)[1,2,4]ТРИАЗОЛО[4,3-a]ПИРИДИНЫ В КАЧЕСТВЕ ИНГИБИТОРОВ c-MET ТИРОЗИНКИНАЗЫ
US20130209543A1 (en) 2011-11-23 2013-08-15 Intellikine Llc Enhanced treatment regimens using mtor inhibitors
SG11201402986RA (en) 2011-12-09 2014-12-30 Chiesi Farma Spa Kinase inhibitors
ES2612259T3 (es) 2011-12-09 2017-05-16 Chiesi Farmaceutici S.P.A. Inhibidores de cinasa
WO2013083206A1 (en) 2011-12-09 2013-06-13 Chiesi Farmaceutici S.P.A. Derivatives of 4-hydroxy-1,2,3,4-tetrahydronaphtalen-1-yl urea and their use in the treatment of, inter alia, diseases of the respiratory tract
ES2894830T3 (es) 2012-04-03 2022-02-16 Novartis Ag Productos combinados con inhibidores de tirosina·cinasa y su uso
AP3902A (en) 2012-06-29 2016-11-17 Pfizer Novel 4-(substituted-amino)-7H-pyrrolo[2,3-d]pyrimidines as LRRK2 inhibitors
CN105246482A (zh) 2013-03-15 2016-01-13 因特利凯有限责任公司 激酶抑制剂的组合及其用途
KR20160018567A (ko) 2013-06-06 2016-02-17 키에시 파르마슈티시 엣스. 피. 에이. 키나아제 억제제
AU2014317600A1 (en) 2013-09-05 2016-03-03 F.Hoffmann-La Roche Ag Triazolopyridine compounds, compositions and methods of use thereof
WO2015084804A1 (en) 2013-12-03 2015-06-11 Novartis Ag Combination of mdm2 inhibitor and braf inhibitor and their use
WO2015092592A1 (en) 2013-12-17 2015-06-25 Pfizer Inc. Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
JP6526789B2 (ja) 2014-07-31 2019-06-05 ノバルティス アーゲー 組み合わせ療法
CN107428750A (zh) 2015-03-04 2017-12-01 豪夫迈·罗氏有限公司 三唑并吡啶化合物及其使用方法
RU2722149C1 (ru) 2015-09-14 2020-05-27 Пфайзер Инк. Новые производные имидазо[4,5-c] хинолинов и имидазо[4,5-c][1,5] нафтиридинов в качестве ингибиторов LRRK2
TW201720828A (zh) 2015-11-23 2017-06-16 赫孚孟拉羅股份公司 治療性化合物及組合物以及其使用方法
AR107165A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa Inhibidores de quinasa
AR107163A1 (es) 2015-12-23 2018-03-28 Chiesi Farm Spa Inhibidores de quinasa
EP3394060A1 (en) 2015-12-23 2018-10-31 Chiesi Farmaceutici S.p.A. 1-(3-tert-butyl-2h-pyrazol-5-yl or 5-tert-butyl-isoxaol-3-yl)-3-(4-([1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalenyl) urea derivatives and their use as p38 mapk inhibitors
EP3452464B1 (en) 2016-05-05 2021-12-15 F. Hoffmann-La Roche AG Pyrazole derivatives, compositions and therapeutic use thereof
EP4198036A1 (en) 2016-09-06 2023-06-21 F. Hoffmann-La Roche AG 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a] pyridinyl compounds, compositions and methods of use thereof
EP3562809B1 (en) 2016-12-29 2021-06-09 F. Hoffmann-La Roche AG Pyrazolopyrimidine compounds and methods of use thereof
JP2020510061A (ja) 2017-03-14 2020-04-02 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft ピラゾロクロロフェニル化合物、組成物及びその使用方法
CA3061236A1 (en) 2017-05-22 2018-11-29 F. Hoffmann-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
EP3630767A1 (en) 2017-05-22 2020-04-08 H. Hoffnabb-La Roche Ag Therapeutic compounds and compositions, and methods of use thereof
US10364245B2 (en) 2017-06-07 2019-07-30 Chiesi Farmaceutici S.P.A. Kinase inhibitors
WO2019139714A1 (en) 2018-01-15 2019-07-18 Genentech, Inc. Pyrazolopyrimidine compounds as jak inhibitors
EP3801069A4 (en) 2018-06-01 2022-03-16 Cornell University MULTIPLE THERAPY FOR DISEASE OR DISORDER ASSOCIATED WITH PI3K
JP7682110B2 (ja) 2019-06-18 2025-05-23 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Jakキナーゼのテトラゾール置換ピラゾロピリミジン阻害剤及びその使用
JP7716993B2 (ja) 2019-06-18 2025-08-01 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト Jakキナーゼのピラゾロピリミジンアリールエーテル阻害剤及びその使用
AU2020297415A1 (en) 2019-06-18 2022-01-06 F. Hoffmann-La Roche Ag Pyrazolopyrimidine sulfone inhibitors of JAK kinases and uses thereof
TW202140550A (zh) 2020-01-29 2021-11-01 瑞士商諾華公司 使用抗tslp抗體治療炎性或阻塞性氣道疾病之方法
CN117343119A (zh) * 2022-06-29 2024-01-05 上海交通大学 一种烷基化核苷、核苷酸、寡核苷酸及其类似物的制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61207400A (ja) * 1985-03-11 1986-09-13 Nippon Zoki Pharmaceut Co Ltd ヌクレオシド化合物の製造方法
US4751292A (en) 1985-07-02 1988-06-14 The Plant Cell Research Institute, Inc. Adamantyl purines
US4859677A (en) 1987-04-17 1989-08-22 University Of Kansas Nucleoside analogues having antiviral activity
US5246931A (en) 1988-10-25 1993-09-21 Bristol-Myers Squibb Company Carbocyclic nucleoside analogs
US5688778A (en) 1989-05-15 1997-11-18 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Nucleoside analogs
GB8916480D0 (en) 1989-07-19 1989-09-06 Glaxo Group Ltd Chemical process
US5763596A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5726302A (en) * 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5276151A (en) 1990-02-01 1994-01-04 Emory University Method of synthesis of 1,3-dioxolane nucleosides
US5470857A (en) 1990-09-14 1995-11-28 Marion Merrell Dow Inc. Carbocyclic nucleoside analogs useful as immunosuppressants
SE9003151D0 (sv) 1990-10-02 1990-10-02 Medivir Ab Nucleoside derivatives
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
GB9204015D0 (en) 1992-02-25 1992-04-08 Wellcome Found Therapeutic nucleosides
TW374087B (en) 1993-05-25 1999-11-11 Univ Yale L-2',3'-dideoxy nucleotide analogs as anti-hepatitis B(HBV) and anti-HIV agents
WO1996004293A1 (en) * 1994-08-02 1996-02-15 Banyu Pharmaceutical Co., Ltd. Antitumor indolopyrrolocarbazoles
US5659023A (en) 1995-02-01 1997-08-19 Gilead Sciences, Inc. Nucleotide analogues
KR19990081940A (ko) 1996-01-23 1999-11-15 그레이엄 브레레톤, 레슬리 에드워즈 항바이러스제로서 변형된 벤즈이미다졸 누클레오시드

Also Published As

Publication number Publication date
ID25992A (id) 2000-11-16
KR20010069193A (ko) 2001-07-23
RU2200738C2 (ru) 2003-03-20
HU0001843D0 (en) 2000-07-28
IN186850B (forum.php) 2001-11-24
BR0002089A (pt) 2001-01-02
CN1275575A (zh) 2000-12-06
HUP0001843A2 (hu) 2001-06-28
KR100403900B1 (ko) 2003-11-01
CZ20001710A3 (cs) 2001-09-12
CA2307951A1 (en) 2000-11-11
YU25500A (sh) 2003-08-29
MXPA00004532A (es) 2002-03-08
TR200001340A2 (tr) 2000-12-21
EP1052264B1 (en) 2005-03-23
EP1052264A2 (en) 2000-11-15
ZA200002263B (en) 2001-12-24
IL136027A0 (en) 2001-05-20
AR028991A1 (es) 2003-06-04
US6271370B1 (en) 2001-08-07
HUP0001843A3 (en) 2001-09-28
ATE291582T1 (de) 2005-04-15
JP2001011092A (ja) 2001-01-16
EP1052264A3 (en) 2001-06-13
DE60018833D1 (de) 2005-04-28
AU3401100A (en) 2000-11-16

Similar Documents

Publication Publication Date Title
PL340109A1 (en) Method of obtaining analogues of nucleosides
PL326882A1 (en) Method of obtaining vanilin
GB2349493B (en) Method of representing an object using shape
EP1242200A4 (en) METHOD FOR PRODUCING "T" COUPLINGS
PL342228A1 (en) Method of obtaining cyclic n-hydroxydicarboxides
PL341648A1 (en) Novel method of obtaining kethymin
HUP0203315A3 (en) Process and intermediates for the preparation of isoxazolecaroxamides and analogues
PL338354A1 (en) Method of obtaining avermectin compounds
PL341752A1 (en) Method of obtaining aryloamino hydroxyantraquinones
SI1406896T1 (sl) Stereoselektivna metoda za pripravo nukleozidnih analogov
PL340733A1 (en) Method of obtaining derivatives of 2-aminothiazocarboxamide
GB9924752D0 (en) Method of construction
PL338405A1 (en) Method of obtaining 2-quinoxalincarboxylic acid
PL325802A1 (en) Method of obtaining polyestroles
PL333334A1 (en) Method of obtaining silylethenes
PL336552A1 (en) Method of obtaining osmotherapeutic mixtures of anhydrohexithioles
AU7019200A (en) Nucleoside analogues
PL340157A1 (en) Method of obtaining derivatives of 2-phenyl-3-aminopyridine
PL333032A1 (en) Method of obtaining nalpha-benzyloxycarbonyl-l-lysine
PL335626A1 (en) Method of obtaining 8beta-hydroxy-19-norandrostendione
PL335627A1 (en) Method of obtaining 8beta-hydroxyandrostendione
PL333385A1 (en) Method of obtaining bisphenoles
PL335392A1 (en) Method of obtaining 4-hydroxy-beta-ionone
GB9816448D0 (en) Synthesis of nucleoside analogues
PL337306A1 (en) Method of obtaining coke

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)